The shares were listed in July 2001 following an equity placement in May 2001 to a group of NZ institutions at 73c per share, raising $6m.
The company commenced business in August 2000 when it acquired from the University of Otago, rights to Salivaricin B, a substance which acts as a natural antibiotic to control streptococcal throat...(more)
This information was extracted from the half year report provided by BLIS Technologies Limited released on 3 November 2014:
BLIS Technologies Limited (the Company) reports an operating loss of $808k on turnover of $1,143k for the six months to September 30, 2014. Turnover increased 59% from the $721k reported in the previous correspon...(more)